# AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

> **NCT05632328** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bruno Bockorny** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** AGEN1423
- **DRUG:** Botensilimab
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05632328
- **Lead sponsor:** Bruno Bockorny
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-08
- **Primary completion:** 2026-05-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05632328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05632328, "AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05632328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*